Literature DB >> 22032578

Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.

A Gabriella Wernicke1, Mark A Edgar, Ehud Lavi, He Liu, Pamela Salerno, Neil H Bander, Philip H Gutin.   

Abstract

CONTEXT: Prostate-specific membrane antigen (PSMA) is expressed in endothelium of vessels in malignant solid tumors but not in normal vessels.
OBJECTIVE: To examine whether neovasculature of glioblastoma multiforme (GBM) expresses PSMA. Design.-After institutional review board approval at Memorial Sloan-Kettering Cancer Center, formalin-fixed paraffin-embedded tissue from 32 patients who underwent a maximally safe neurologic resection during 2004 to 2005 for GBM (World Health Organization criteria) was obtained. We performed immunohistochemical staining on the vessels of the GBM specimens for PSMA expression in tumor endothelium. The tissue samples were also stained for CD31 to verify that the PSMA was staining tumor vessels. The PSMA percent staining was scored: less than 5%, 6% to 25%, 26% to 50%, 51% to 75%, and 76% to 100%. Staining intensity was ranked as follows: 0 (none), 1+ (faint), 2+ (moderately-intense), and 3+ (maximum-intensity).
RESULTS: Immunohistochemical staining on the vessels of 32 paraffin-embedded GBM specimens revealed that all 32 (100%) specimens exhibited staining for PSMA to a variable extent. Of these, 22 of 32 specimens (69%) had more than 51% vascular staining for PSMA. The intensity of staining was 2+ to 3+ in most of the specimens (29 of 32; 91%).
CONCLUSIONS: Prostate-specific membrane antigen is expressed in the vasculature of GBM vessels, thus rendering a potential novel therapeutic vascular target. A clinical trial with a cytotoxin-conjugated antibody to PSMA is planned.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22032578     DOI: 10.5858/arpa.2010-0740-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  45 in total

1.  Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas.

Authors:  Roberto Andres Salas Fragomeni; Joshua R Menke; Matthias Holdhoff; Clare Ferrigno; John Joseph Laterra; Lilja B Solnes; Mehrbod S Javadi; Zsolt Szabo; Martin G Pomper; Steven P Rowe
Journal:  Clin Nucl Med       Date:  2017-10       Impact factor: 7.794

2.  In vivo visualization of prostate-specific membrane antigen in glioblastoma.

Authors:  Johannes Schwenck; Ghazaleh Tabatabai; Marco Skardelly; Gerhald Reischl; Rudi Beschorner; Bernd Pichler; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-08       Impact factor: 9.236

3.  MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound.

Authors:  Raag D Airan; Catherine A Foss; Nicholas P K Ellens; Yuchuan Wang; Ronnie C Mease; Keyvan Farahani; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

4.  The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?

Authors:  Marcus Unterrainer; Maximilian Niyazi; Viktoria Ruf; Peter Bartenstein; Nathalie L Albert
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

5.  Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy.

Authors:  Jolanta Kunikowska; Królicki Bartosz; Królicki Leszek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-31       Impact factor: 9.236

6.  Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody.

Authors:  Masahide Matsuda; Eiichi Ishikawa; Tetsuya Yamamoto; Kentaro Hatano; Akira Joraku; Yuichi Iizumi; Yosuke Masuda; Hiroyuki Nishiyama; Akira Matsumura
Journal:  J Neurooncol       Date:  2018-03-09       Impact factor: 4.130

Review 7.  Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors:  A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-07-24       Impact factor: 2.346

8.  PSMA-targeted theranostic nanoplex for prostate cancer therapy.

Authors:  Zhihang Chen; Marie-France Penet; Sridhar Nimmagadda; Cong Li; Sangeeta R Banerjee; Paul T Winnard; Dmitri Artemov; Kristine Glunde; Martin G Pomper; Zaver M Bhujwalla
Journal:  ACS Nano       Date:  2012-08-09       Impact factor: 15.881

Review 9.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

10.  PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.

Authors:  Zhihang Chen; Marie-France Penet; Balaji Krishnamachary; Sangeeta R Banerjee; Martin G Pomper; Zaver M Bhujwalla
Journal:  Biomaterials       Date:  2015-12-02       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.